Megna Michael R reported option exercise involving 11,280 derivative units of Kiniksa Pharmaceuticals International, plc at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CHIEF ACCOUNTING OFFICER
CHIEF ACCOUNTING OFFICER
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
11,280Share Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
5,114Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 12, 2026, 4:33 PM ET3-day reporting delay
Accession
0001464583-26-000012Code M · Transaction 399119
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell11,280$98.54−$1,111,531.20Trade 399118
Nov 9, 2026Option exercise11,280$17.76$200,332.80Trade 399117
3 transaction rows in this filing. Joint filers share the same rows.

KNSA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KNSA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −17%1w ago −1.1%1d ago −2.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $98.48 and $98.64. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.